Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is quickly establishing itself as a major player, ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Unlike semaglutide or liraglutide that only activate the GLP-1 receptor, the dual agonist tirzepatide works on the GLP-1 and GIP receptors, two important hormone pathways that help control hunger. As ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo Nordisk and UnitedHealth Group have been beaten down to less than half their ...